Case Study: Biotechnology Patent Landscape Analysis Case Study: Mapping the Gene-Editing and Delivery White Space Before a Series B

This biotechnology patent landscape analysis case study follows a clinical-stage gene-editing company through the competitive-intelligence review it ran before a Series B and before it locked the editor and delivery architecture of its lead program. Biotechnology is one of the few life-science fields still gaining patent momentum: the EPO Patent Index 2024 recorded biotechnology filings up 5.4% to 8,479 — one of the office’s fastest-growing fields — even as pharmaceutical filings fell 13.2% to 8,359 in the same year. Underneath that headline sits a uniquely contested terrain. WIPO counted more than 11,000 CRISPR-related patent families already on file by late 2024, against an estimated US$3.78 billion invested in CRISPR startups. A founder cannot tell a Series-B room “the science is ours” into a field like that without knowing who holds the foundational patents, where the thickets are, and where a defensible, licensable position still exists. The scenario below shows the exact sequence PerspireIP runs, the public data it is built on, and where the analysis changed the plan.

The Challenge: Building a Gene-Editing Therapy on Contested Foundational IP

The client, a venture-backed biotech developing an in-vivo base-editing therapy delivered by lipid nanoparticle (LNP), had compelling preclinical data and a term sheet in view. What it lacked was an evidence-based read of the patent terrain across two stacked technologies — the editor (a CRISPR-derived base editor) and the delivery (an mRNA/LNP system). Investor diligence in the prior round had raised two questions the team could not yet answer with evidence: what can you actually own, and what will you have to license or design around before you dose a patient?

Three realities made those questions hard. First, the foundational layer is split and litigated. WIPO’s landscape notes that the Broad Institute’s eukaryotic CRISPR-Cas9 patent was granted as early as April 2014 and that the USPTO reaffirmed Broad’s priority for use in eukaryotic cells in 2022, while the University of California holds foundational claims reaching CRISPR-Cas9 across cell types — so a product in human cells can read on both estates at once.

Second, the field is crowded with heavyweight filers: assignee counts in the CRISPR corpus are led by the University of California, Harvard, Regeneron, MIT and the Broad Institute, each with more than 3,000 patent records. Third, the delivery layer is its own thicket — the mRNA/LNP patent family set now exceeds 16,000 families with three-year filings running roughly 52% above the prior window, led by Moderna with over 2,000 families. Owning an editor means nothing if you cannot deliver it without infringing.

The client needed a competitive biotechnology patent landscape it could put in front of investors and its own R&D leads: a defensible map of who holds what across editor and delivery, where the crowding is genuine versus superficial, which foundational estates it would have to license, and which technical clusters were still open enough to build its own filing program around.

Our Approach: A Five-Stage Competitive Patent Landscape Analysis

PerspireIP structured the biotechnology patent landscape analysis as five sequential stages, each narrowing the field from the whole gene-editing-and-delivery corpus down to the handful of clusters that actually mattered to this client’s program. The method is the same competitive-intelligence sequence described on our competitive IP intelligence service page, tuned here for the sector we cover in depth on our biotechnology market-research page.

1. Corpus definition and search. We built the search from primary classification rather than keywords alone — CPC/IPC codes for nucleic-acid enzymes and CRISPR systems (C12N 9/22, C12N 15/11), base/prime editing, and lipid-nanoparticle and mRNA delivery — then queried Espacenet, WIPO PATENTSCOPE and the USPTO full-text datasets to capture families across the U.S., EPO, PCT, CNIPA and the major national offices. The result was deduplicated to roughly 2,600 in-scope families spanning editor and delivery.
2. Assignee benchmarking. We resolved noisy assignee names to ultimate parents and ranked the 42 organizations with meaningful positions in the client’s technical neighborhood — separating operating competitors (Moderna, Intellia, Beam, Regeneron and the LNP specialists) from the research institutions (University of California, Broad Institute, Harvard, MIT) that file heavily but license rather than assert.
3. Technology-cluster mapping. We clustered the families by problem solved — not by company — so the client could see where filings concentrate (Cas9 nuclease architecture, canonical LNP formulations) and where they thin out (tissue-specific targeting ligands, editor variants with reduced off-target activity).
4. White-space and freedom-to-operate screen. Against those clusters we located four pockets of genuine white space adjacent to the client’s roadmap, and separately flagged six families — two foundational Cas9 estates and four delivery families held by operating competitors — that read close enough to the planned product to require a license, a pool, or a claim-charting FTO study.
5. Strategic readout. Findings were translated into a licensing-and-filing plan, an investor-ready landscape narrative, and a watch list keyed to the assignees and clusters most likely to move.

What the Landscape Analysis Surfaced

Mapping filings by problem rather than by company reframed the client’s assumptions:

• The foundational layer needs two licenses, not one. Because a therapy in human cells can read on both the Broad eukaryotic Cas9 estate and the University of California’s cross-cell-type claims, the realistic path was a license from each pool — a cost and timeline the team had treated as a single line item.
• Delivery, not the editor, was the real chokepoint. The editor science was differentiated, but the LNP delivery cluster is densely patented and dominated by a few operating competitors with over 16,000 mRNA/LNP families in the wider field. That is where the live infringement risk sat — and where a design-around had the most value.
• Four white-space clusters sat next to the roadmap. Tissue-specific targeting ligands, base-editor variants with reduced off-target profiles, and two manufacturing/formulation niches showed thin, fragmented coverage — exactly the areas where the client’s own work was strongest. That is where we recommended it concentrate provisional filings.
• Filers who assert are not the biggest filers. The University of California and Broad lead the CRISPR corpus on volume, but they license rather than sue; the families that actually threatened the program were held by operating companies. Benchmarking that distinguishes an academic estate from a competitor’s is what kept the FTO list short and real.

The Outcome: A Fundable, Licensable IP Position

The analysis did not slow the raise — it made the plan honest. With the landscape in hand, the client was able to:

• Answer investor diligence with an evidence-based landscape narrative — a documented map of editor and delivery estates — instead of the assertion that “the science is ours.”
• Budget a realistic dual foundational license from the Broad and University of California estates, rather than discovering the second estate after the round closed.
• Redirect its provisional-filing budget toward the four white-space clusters where claims were both attainable and aligned with its differentiation, instead of filing into crowded Cas9 and canonical-LNP art.
• Commission a focused freedom-to-operate claim-charting study on the six flagged families — and scope an LNP design-around — before finalizing the delivery system, converting an unknown into a costed engineering decision.
• Stand up a competitor watch list keyed to the ranked assignees and clusters, so a field adding thousands of families a year is monitored rather than rediscovered every round.

The difference was between a founder’s belief that a space is open and a documented map that shows exactly where it is, what it costs to enter, and what must be licensed first — the proof a Series-B data room and a development plan both require.

Lessons for Biotechs Scoping the Field

• Map the whole stack, not just your molecule. In gene editing the editor and the delivery system are separately patented; a landscape that stops at the editor misses where the real freedom-to-operate risk usually lives.
• Treat foundational CRISPR as a two-estate problem. With the Broad and University of California claims reaching overlapping subject matter, a human-cell therapy frequently needs a position with respect to both — budget and diligence should assume it until proven otherwise.
• Separate filers who assert from filers who don’t. Universities dominate the CRISPR corpus by volume but license rather than sue; benchmarking must distinguish an academic estate from an operating competitor’s family, or the FTO list balloons with phantom risk.
• Map white space to your own roadmap. The value is not a heat map — it is the specific, attainable clusters where your science can become defensible IP before someone else files there.

Why the 2024 Numbers Made This Analysis Urgent

The scenario above is grounded in a genuine 2024 shift that any current biotechnology patent landscape analysis has to account for. The EPO Patent Index 2024 recorded biotechnology filings up 5.4% to 8,479 — one of the office’s fastest-growing fields — while pharmaceutical filings fell 13.2% to 8,359. The two life-science fields moved in opposite directions in the same year. A landscape built on last year’s assumption that pharma and biotech rise together would misread where filing energy now concentrates.

Geography compounds the point. WIPO reports roughly 273,900 PCT applications in 2024, with Asia now accounting for 56.3% of the total. For gene editing, where Chinese and Korean offices receive heavy filing volume, a landscape that reads only U.S. and English-language patents is not a landscape — it is a blind spot dressed as good news. That is why the method starts from CPC and IPC classification and searches Espacenet, PATENTSCOPE and the national datasets together, rather than running keyword queries against a single office.

The delivery layer is accelerating hardest of all. Published analyses put the mRNA and lipid-nanoparticle corpus at more than 16,000 patent families, with the most recent three-year window running about 52% ahead of the prior one; Moderna alone holds over 2,000 families. Filing counts in early 2025 were well above the same period a year earlier. A snapshot of the delivery field is stale within quarters, so the readout includes a watch list rather than a one-time map.

Finally, the foundational CRISPR history is settled enough to plan around but contested enough to respect. The first filings by Doudna and Charpentier date to 2012; the Broad Institute’s eukaryotic patent was granted in 2014; the inventors shared the 2020 Nobel Prize in Chemistry; and the USPTO reaffirmed the Broad’s eukaryotic priority in 2022. For a company building in human cells, the practical takeaway is not who “won” — it is that the two leading estates reach overlapping subject matter, so a realistic freedom-to-operate plan assumes a position with respect to each.

Put together, these four facts are why a biotechnology patent landscape analysis front-loads classification and assignee resolution and ends with the freedom-to-operate screen. The output that changes a decision — what must be licensed, what can be owned, and what is moving too fast to ignore — needs to arrive before a financing round closes or a delivery architecture is locked, not after.

Data Sources

The market and patent data referenced above comes from:

• EPO — Patent Index 2024 — Biotechnology filings rose 5.4% to 8,479 in 2024 (one of the fastest-growing fields) while pharmaceuticals fell 13.2% to 8,359; the EPO received 199,264 applications in 2024.
• WIPO — CRISPR-Cas: Navigating the Patent Landscape (Nov 2024) — Over 11,000 CRISPR-related patent families filed; an estimated US$3.78 billion invested in CRISPR startups; Broad eukaryotic Cas9 patent granted April 2014 and USPTO reaffirmed Broad priority in 2022.
• WIPO — PCT Yearly Review 2024 — About 273,900 PCT applications were filed in 2024; biotechnology had one of the highest shares of women inventors among all fields at 31.9%.
• PatSnap — CRISPR Gene Editing Patent Landscape — A ~17,590-family CRISPR corpus led by the University of California (3,953 records), Harvard (3,653), Regeneron (3,263), MIT (3,262) and the Broad Institute (3,119).

Discuss a Similar Matter

Frequently Asked Questions